This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient.
Wen‐Zhi Guo, Hong‐Bo Fang, Sheng‐Li Cao, San‐Yang Chen, Jie Li, Ji‐Hua Shi, Hong‐Wei Tang, Yi Zhang, Pei‐Hao Wen, Jia‐Kai Zhang, Zhi‐Hui Wang, Xiao‐Yi Shi, Chun Pang, Han Yang, Bo‐Wen Hu, Shui‐Jun Zhang – 8 August 2019
Feng Zhou, Jianghua Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li – 7 August 2019
Yuankai Wu, Yee Hui Yeo, Mindie H. Nguyen, Ramsey C. Cheung – 7 August 2019
Hassan Azhari, Mark G. Swain – 7 August 2019
Kavita Radhakrishnan, Adrian M. Di Bisceglie, K. Rajender Reddy, Joseph K. Lim, Josh Levitsky, Mohamed A. Hassan, Jama M. Darling, Jordan J. Feld, Lucy Akushevich, Monika Vainorius, David R. Nelson, Michael W. Fried, Robert S. Brown, Norah A. Terrault – 7 August 2019 – Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs).
Jérôme Boursier, Sven Francque – 5 August 2019
Ying Zhou, Bingning Dong, Kang Ho Kim, Sungwoo Choi, Zhen Sun, Nan Wu, Yifan Wu, Jessica Scott, David D. Moore – 5 August 2019
Francesco De Chiara, Karen Louise Thomsen, Abeba Habtesion, Helen Jones, Nathan Davies, Jordi Gracia‐Sancho, Nicolò Manicardi, Andrew Hall, Fausto Andreola, Hannah L. Paish, Lee H. Reed, Abigail A. Watson, Jack Leslie, Fiona Oakley, Krista Rombouts, Rajeshwar Prosad Mookerjee, Jelena Mann, Rajiv Jalan – 5 August 2019